Organised by Reckitt
Chair(s)
TBC
Introduction:
Discover DGBI new treatments available. Benefits of combinations of xyloglucan + pea protein in the treatment of IBS type symptoms and the role of these new products in pharmacist’s repertoire of treatments. The importance of Pharmacists in the management of IBS.
Programme:
| 08:00 – 08:05 | Chair introduction | |
| 08:05 – 08:30 | Latest thinking on DGBIs & new treatments |
| Prof. Javier Santos, Head of Clinical Gastroenterology and Pancreas, Vall d'Hebron - Hospital Universitari, Vall d'Hebron Hospital Campus, Spain | |
| 08:30 – 08:45 | Review of case studies of patients presenting to pharmacy |
| Dr Elsa López Pintor, Associate Professor, Area of Pharmacy and Pharmaceutical Technology, Universidad Miguel Hernández, Alicante, Spain. Spanish Institute of Health Carlos III, CIBER in Epidemiology and Public Health (CIBERESP) | |
| 08:45 – 08:55 | Q&A |
| 08:55 – 09:00 | Key observations and closing remarks |
Understand the incidence & pathophysiology of IBS (Identification of IBS subtypes, causes, how gut brain interactions, microbiome imbalances and motility disorders contribute to IBS symptoms.
2. Management - Review the conventional and established treatments (pharmacological, diet, behaviors & lifestyle.
3. Explore emerging therapies (clinical evidence behind xyloglucan + pea protein) for DGBI.
4. Assess patient-centred approaches (understand how treatment choices vary by patient preferences, subtype and symptom severity).
5. Role of pharmacists in the management of DGBI being IBS as the prominent disease.
Take home messages:
Disorders of Gut-Brain Interaction (DGBI) have complex pathophysiology and affect more than 40% of people worldwide. Around 15% of people in EU are suffering with irritable bowel syndrome. Patients are dissatisfied with their current solutions and Pharmacists can help them to open up the conversation about symptoms and tailored options/solutions. There are new options available in the markets that work by targeting the underlying cause of IBS.
